vs
Side-by-side financial comparison of ENANTA PHARMACEUTICALS INC (ENTA) and FVCBankcorp, Inc. (FVCB). Click either name above to swap in a different company.
ENANTA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($18.6M vs $16.9M, roughly 1.1× FVCBankcorp, Inc.). On growth, FVCBankcorp, Inc. posted the faster year-over-year revenue change (4377.5% vs 9.8%). FVCBankcorp, Inc. produced more free cash flow last quarter ($23.8M vs $-11.8M). Over the past eight quarters, FVCBankcorp, Inc.'s revenue compounded faster (586.6% CAGR vs 4.5%).
Enanta Pharmaceuticals Inc is a clinical-stage biotechnology company that develops innovative antiviral therapies for infectious diseases including hepatitis B virus, respiratory syncytial virus (RSV), and SARS-CoV-2. It operates primarily in the U.S. and global markets, partnering with pharmaceutical firms to advance its small molecule drug candidate pipeline for patients with unmet medical needs.
FVCBankcorp, Inc. is a Virginia-based U.S. bank holding company operating FVCbank, a community-focused financial institution. It provides a full range of personal and commercial banking products including deposit accounts, business and personal loans, mortgage services, and wealth management solutions, serving SMEs, professionals and individual consumers across the Mid-Atlantic region.
ENTA vs FVCB — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.6M | $16.9M |
| Net Profit | $-11.9M | — |
| Gross Margin | — | — |
| Operating Margin | -60.5% | 43.7% |
| Net Margin | -64.1% | — |
| Revenue YoY | 9.8% | 4377.5% |
| Net Profit YoY | 46.4% | — |
| EPS (diluted) | $-0.42 | $0.31 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $18.6M | $16.9M | ||
| Q3 25 | $15.1M | $416.0K | ||
| Q2 25 | $18.3M | $15.8M | ||
| Q1 25 | $14.9M | $382.0K | ||
| Q4 24 | $17.0M | $378.0K | ||
| Q3 24 | $14.6M | $412.0K | ||
| Q2 24 | $18.0M | $415.0K | ||
| Q1 24 | $17.1M | $359.0K |
| Q4 25 | $-11.9M | — | ||
| Q3 25 | $-18.7M | $5.6M | ||
| Q2 25 | $-18.3M | $5.7M | ||
| Q1 25 | $-22.6M | $5.2M | ||
| Q4 24 | $-22.3M | — | ||
| Q3 24 | $-28.8M | $4.7M | ||
| Q2 24 | $-22.7M | $4.2M | ||
| Q1 24 | $-31.2M | $1.3M |
| Q4 25 | -60.5% | 43.7% | ||
| Q3 25 | -121.6% | — | ||
| Q2 25 | -103.2% | 45.9% | ||
| Q1 25 | -164.3% | — | ||
| Q4 24 | -138.8% | — | ||
| Q3 24 | -204.4% | — | ||
| Q2 24 | -134.6% | — | ||
| Q1 24 | -192.1% | — |
| Q4 25 | -64.1% | — | ||
| Q3 25 | -123.6% | 1341.1% | ||
| Q2 25 | -99.7% | 36.0% | ||
| Q1 25 | -151.7% | 1352.1% | ||
| Q4 24 | -131.4% | — | ||
| Q3 24 | -197.3% | 1133.3% | ||
| Q2 24 | -126.1% | 1001.2% | ||
| Q1 24 | -182.7% | 373.3% |
| Q4 25 | $-0.42 | $0.31 | ||
| Q3 25 | $-0.88 | $0.31 | ||
| Q2 25 | $-0.85 | $0.31 | ||
| Q1 25 | $-1.06 | $0.28 | ||
| Q4 24 | $-1.05 | $0.27 | ||
| Q3 24 | $-1.36 | $0.25 | ||
| Q2 24 | $-1.07 | $0.23 | ||
| Q1 24 | $-1.47 | $0.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $37.4M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $126.6M | $253.6M |
| Total Assets | $329.5M | $2.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $37.4M | — | ||
| Q3 25 | $32.3M | — | ||
| Q2 25 | $44.8M | — | ||
| Q1 25 | $60.2M | — | ||
| Q4 24 | $84.3M | — | ||
| Q3 24 | $37.2M | — | ||
| Q2 24 | $35.8M | — | ||
| Q1 24 | $63.5M | — |
| Q4 25 | $126.6M | $253.6M | ||
| Q3 25 | $64.7M | $249.8M | ||
| Q2 25 | $79.3M | $243.2M | ||
| Q1 25 | $93.5M | $242.3M | ||
| Q4 24 | $111.8M | $235.4M | ||
| Q3 24 | $128.8M | $230.8M | ||
| Q2 24 | $148.9M | $226.5M | ||
| Q1 24 | $166.1M | $220.7M |
| Q4 25 | $329.5M | $2.3B | ||
| Q3 25 | $280.7M | $2.3B | ||
| Q2 25 | $301.0M | $2.2B | ||
| Q1 25 | $323.0M | $2.2B | ||
| Q4 24 | $348.6M | $2.2B | ||
| Q3 24 | $376.7M | $2.3B | ||
| Q2 24 | $398.8M | $2.3B | ||
| Q1 24 | $413.6M | $2.2B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-11.7M | $23.9M |
| Free Cash FlowOCF − Capex | $-11.8M | $23.8M |
| FCF MarginFCF / Revenue | -63.6% | 140.7% |
| Capex IntensityCapex / Revenue | 0.8% | 0.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-18.5M | $40.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-11.7M | $23.9M | ||
| Q3 25 | $-6.5M | $7.6M | ||
| Q2 25 | $17.5M | $3.3M | ||
| Q1 25 | $-13.5M | $5.4M | ||
| Q4 24 | $-16.8M | $18.2M | ||
| Q3 24 | $-10.4M | $4.7M | ||
| Q2 24 | $-14.8M | $1.6M | ||
| Q1 24 | $-28.6M | $7.2M |
| Q4 25 | $-11.8M | $23.8M | ||
| Q3 25 | $-7.9M | $7.6M | ||
| Q2 25 | $17.4M | $3.3M | ||
| Q1 25 | $-16.0M | $5.4M | ||
| Q4 24 | $-25.5M | $18.1M | ||
| Q3 24 | $-19.4M | $4.6M | ||
| Q2 24 | $-21.3M | $1.5M | ||
| Q1 24 | $-30.3M | $7.1M |
| Q4 25 | -63.6% | 140.7% | ||
| Q3 25 | -52.5% | 1818.0% | ||
| Q2 25 | 94.7% | 20.8% | ||
| Q1 25 | -107.4% | 1413.6% | ||
| Q4 24 | -150.6% | 4786.0% | ||
| Q3 24 | -132.5% | 1121.8% | ||
| Q2 24 | -118.6% | 361.2% | ||
| Q1 24 | -177.5% | 1988.3% |
| Q4 25 | 0.8% | 0.3% | ||
| Q3 25 | 9.6% | 0.2% | ||
| Q2 25 | 0.8% | 0.1% | ||
| Q1 25 | 17.0% | 4.2% | ||
| Q4 24 | 51.6% | 37.3% | ||
| Q3 24 | 61.3% | 14.1% | ||
| Q2 24 | 36.4% | 12.8% | ||
| Q1 24 | 9.8% | 3.9% |
| Q4 25 | — | — | ||
| Q3 25 | — | 1.36× | ||
| Q2 25 | — | 0.58× | ||
| Q1 25 | — | 1.05× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.00× | ||
| Q2 24 | — | 0.37× | ||
| Q1 24 | — | 5.34× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
